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     INTRODUCTION 
 
 
Pneumonias are a major cause of morbidity and mortality among all ages of people. The 
leading cause for community acquired pneumonia requiring hospitalization in about 36% 
of the adult population is Streptococcus pneumoniae. This organism also causes other 
invasive and life threatening conditions such as bacterial meningitis and streptococcal 
bacteraemia. It is estimated that nearly 400,000 children under the age of 5 years and an 
equal number of adults, die of pneumonia each year in India. 
Although young children have the highest rates of pneumococcal disease, elderly persons 
and adults with certain chronic illnesses are also at high risk for invasive pneumococcal 
diseases.  Invasive pneumococcal disease has a mean mortality of about 10% among 
normal individuals and this increase within the susceptible population.  
The increased burden of Pneumococcal disease emphasizes the need for preventive 
measures, namely vaccination. The efficacy of Pneumococcal vaccine in preventing 
invasive pneumococcal infections has been found to be about 75%.  
There is very little data on the use of Pneumococcal vaccine in India. Since invasive 
pneumococcal infections remain a major killer, it becomes necessary to study the use of 
Pneumococcal vaccine, including vaccination coverage and protective efficacy among the 
susceptible Indian population. 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVE: 
1. To determine the protective efficacy of Pneumococcal vaccine in a cohort of 
susceptible population in the Medical OPD followed up for a period of six months 
to one year. 
 
SECONDARY OBJECTIVES: 
2. To determine the rate of Pneumococcal vaccination among adult subjects who 
visit the Medical OPD and fulfill the criteria for vaccination. 
3. To describe the current prescribing practices among physicians in the Medical 
OPD. 
4. To identify the determinants of non vaccination among patients presenting to the 
Medical OPD. 
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LITERATURE  REVIEW 
Introduction 
Pneumococcal infections remain a major cause of morbidity and mortality worldwide in 
spite of the availability of vaccines (1). The major cause of community acquired 
pneumonia in adults is Streptococcus pneumoniae (pneumococcus) (2, 3). Streptococcus 
pneumoniae can result in conditions ranging from nasopharyngeal colonization to otitis 
media, and invasive diseases such as meningitis, sepsis, bacteraemia, or pneumonia. S. 
pneumoniae may account for 30% to 50% of all adult community acquired pneumonias 
(CAP) requiring hospital admission and may also be the most frequent cause of 
pneumonia in long term care institutions (4, 5). A meta-analysis of 122 reports of CAP 
between 1966 and 1995 showed that S. pneumoniae caused 66% of nearly 7,000 cases 
having an established etiology(6) . 
Although young children have the highest rates of pneumococcal disease, elderly persons 
and adults with certain chronic illnesses are also at high risk for invasive pneumococcal 
disease, and in industrialized countries, they are much more likely to die of 
pneumococcal disease than are children(7). Bacterial pneumonia and influenza together 
are the fifth leading cause of death in the elderly (people 65 years old and older)(8). 
According to the 1997 ACIP statement, people aged 2–64 years who have chronic 
illnesses that place them at moderate to high risk for pneumococcal disease or 
complications of pneumococcal disease should receive pneumococcal polysaccharide 
vaccine. These people include those with chronic cardiovascular disease (e.g., coronary 
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artery disease, congestive heart failure or cardiomyopathies), chronic pulmonary disease 
(e.g., chronic obstructive pulmonary disease or emphysema, but not asthma), diabetes 
mellitus, alcoholism, chronic liver disease (e.g., cirrhosis), CSF leaks, or functional or 
anatomic asplenia (7). 
Burden of pneumococcal disease 
The reported annual incidence of pneumococcal infections worldwide is between 130 and 
210 cases for every 100,000 inhabitants, but the rate is higher in elderly persons and in 
patients with a compromised immune system(9). Recent data suggest that the rate of CAP 
in the US is 18.2 cases per 1,000 person-years in persons aged 65 to 69 years, rises to 
52.3 cases per 1,000 person-years in those aged 85 years and older, and in nursing home 
residents, the rates of CAP are estimated to be more than 300 cases per 1,000 person-
years(10-12). The annual incidence of invasive infections due to Streptococcus 
pneumoniae in adults older than 64 years in Chile, in a follow up period of five years, has 
been reported to be 234/100,000(13).  
The organism colonizes the upper respiratory tract in approximately 50% of children and 
2.5 % of adults (14). It can cause a wide spectrum of illnesses: upper respiratory tract 
infections including otitis media and sinusitis; pneumonia and other lower respiratory 
tract infections; and disseminated invasive infections, including bacteraemia and 
meningitis (7). Pneumococci that are resistant to penicillin and to multiple agents are 
becoming increasingly common among patients in all age groups, which makes 
pneumococcal infections more difficult to treat(15). The emergence of antibiotic-resistant 
pneumococci has placed renewed emphasis on the importance of disease prevention. 
 xi
Humans are the only reservoir for these bacteria, hence it is theoretically possible to 
eradicate pneumococci by sufficient vaccination, similar to the pox virus. 
Invasive pneumococcal disease has a mean mortality of 10%, which may rise to >30% in 
risk groups (e.g. nursing home residents >65 years of age)(16). In Germany, the 
incidence of these invasive pneumococcal diseases is between 4.6/1,00,000/year for 
patients <65 years and 16.2/100 000/year for patients ≥65 years (17) 
Pneumococcal bacteriology and antibiotic resistance 
 Streptococcus pneumoniae is a Gram-positive encapsulated bacterium. The bacterial 
polysaccharide capsule contributes to the overall virulence of the pathogen and protects 
the bacterium from phagocytosis. Uncapsulated pneumococci such as the laboratory 
reference strain R6 are considered to be non-pathogenic. Ninety-one different capsular 
types (i.e. serotypes) have been described so far. Serotypes that are assessed by cross-
reacting antibodies are summarised in serogroups. 
Increased pneumococcal resistance worldwide is mainly due to the spread of multi 
resistant clones of the pathogen(18).The current nomenclature of these clones is defined 
by the Pneumococcus Molecular Epidemiology Network and consists of the country of 
origin, the serotype (in superscript) and a consecutive number (e.g. Spain23F-1 or 
England14-9(19). Current data demonstrate that pneumococcal resistance has also become 
a problem in countries with traditionally low resistance rates, such as Germany. A 
German study, which included children and adolescents <16 years of age suffering from 
invasive pneumococcal infections, showed that almost 29% of the pneumococci isolated 
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were macrolide-resistant (20). Thus, the proportion of macrolide-resistant species has 
increased three-fold in just 7 years (1997, 8.7%; 2004, 29%). Macrolide-resistant strains 
are of particular interest because macrolide resistance is associated with clinical treatment 
failure(21). In contrast to penicillin resistance, which might be relevant in the treatment 
of pneumococcal pneumonia only at very high minimum inhibitory concentrations 
(MICs) (>4 mg/L)(22), a Canadian observational study identified 64 so-called ‘breaking 
through bacteraemias’ during macrolide treatment. MIC determination of these isolates 
revealed that even slightly elevated MICs of ≥1 mg/L may lead to treatment failure (21). 
Seroprevalence of pneumococcal infections 
Determination of the seroprevalence of naturally developing antibodies to a pathogen 
within a population has proved to be useful in providing data on the epidemiology of 
infection (23) . The bacterial species Streptococcus pneumoniae consists of 90 
immunologically distinct serotypes, of which some possess distinct epidemiological 
properties. Certain serotypes are much more likely to be associated with nasopharyngeal 
colonisation than to cause invasive disease. Compared with transient or infrequent 
colonisers, serotypes carried at high rates by young children may rapidly elicit age-
associated natural immunity to invasive disease. Other serotypes seem to be of 
disproportionate importance as causes of disease in very young infants, in older children, 
in immunocompromised individuals, or in elderly people. Some serotypes seem to be 
associated with particular disease syndromes, such as complicated pneumonias in 
children, or with higher rates of hospitalisation in children or mortality in adults, or are 
consistently responsible for outbreaks in certain populations(24). 
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In a study done from Kenya, the descriptive epidemiology of Streptococcus pneumoniae 
in nasal swabs of adults and children in the Kilifi district of Kenya was done. In the dry 
season, 127 strains of S. pneumoniae were isolated; 4 individuals were infected 
simultaneously with two serotypes. Two strains could not be typed and the remaining 125 
strains expressed 36 capsular types. In the rainy season survey, 152 strains expressing 31 
different serotypes, were isolated from 146 individuals; 6 individuals were infected 
simultaneously with two serotypes. Seventeen individuals carried the same serotype in 
the two studies, of whom sixteen were aged <5 years. These strains were of serotypes 
19F, 6B, 6A, 23B, 9V, 18F and 15A. Overall, 40 different pneumococcal serotypes were 
identified in the two surveys (25). 
The IBIS study was a prospective, hospital-based surveillance study in six large academic 
referral hospitals of the International Clinical Epidemiology Network (INCLEN) which 
was done to assess the seroprevalence of invasive pneumococcal disease in Asia. 
Children aged younger than 12 years with any of the following clinical syndromes: 
pneumonia with radiographic evidence or meeting WHO clinical criteria, clinically 
suspected meningitis or cerebrospinal fluid (CSF) suggestive of bacterial meningitis; and 
fever at least 39°C for 2 days or less, with suspected bacterial infection due to S 
pneumoniae were recruited. Adults with clinical or radiographic evidence of pneumonia, 
or CSF findings suggestive of bacterial meningitis were eligible for inclusion. 6025 
biological samples were collected from 5538 patients recruited by clinical criteria(26).  
The most common serotype was type 1, which has largely disappeared from many 
developed countries (27, 28), but accounts for about 25% of Indian invasive isolates. 
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Serotype 6, which is the most common serotype in developed countries, was the second 
most common in this study, causing only 11·5% of the invasive infections (28). The 
proportion of isolates comprising the most frequent ten serotypes did not differ between 
study centres, and serotype 1 was the most common in all regions in the study. The most 
common serotypes in adults aged more than 65 years were serotype 1, 7, 3, 6, 8, 12, 16, 
4, 9 and 14 (29). 
Substantial differences in serotypes involved with invasive disease were found in 
different age-groups. In young children, S pneumonia types 6 and 19 seemed to be more 
common. A report from Bangladesh showed a different pattern of invasive serotype 
distribution and serotype 6 was not isolated from young children(30). However, the 
Bangladesh study population consisted of only children less than 5 years and 91% were 
younger than 2 years. Serotype 1 infection increased with age in these patients. There 
were no significant differences in the distribution of serotypes across the 4 years of the 
study. 
A one-year prospective surveillance study from in three health care centers in Chile 
included blood culture in infants with suspected invasive bacterial disease or with fever 
higher than 39°C (axillary temperature) without focus or with acute otitis media . Out of 
4,369 infants studied, 58 cases of invasive bacterial diseases were identified, 37 (64%) 
due to S. pneumoniae. The main serotypes identified were 18C, 14 , 19A(31). 
Data from the Canadian National Centre for Streptococcus indicate the proportion of 
invasive pneumococcal isolates with reduced penicillin susceptibility increased from 
5.5% to 15.2% between 1992 and 2000(32). The Canadian Bacterial Surveillance 
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Network has documented a similar trend of decreasing susceptibility to penicillin and to 
other antibiotics among pneumococcal isolates recovered from invasive, respiratory and 
other sites, between 1988 and 2001(33). 
Immune responses induced by Streptococcus pneumoniae 
  Besides phagocytosis and intracellular killing by alveolar macrophages and neutrophil 
granulocytes (innate immunity), acquired humoral immunity is an important part of the 
host defence against pneumococci. As in other bacterial infections eliciting humoral 
responses, such a response requires processing and presentation of bacterial antigen in 
secondary lymphoid tissues(34). 
Immature dendritic cells process and present pneumococcal peptides along with MHC II 
complexes to naive CD4+ T-cells in the presence of co-stimulatory molecules such as 
CD80 and CD86. Such peptide antigen presentation results in T-cell proliferation and 
expansion of effector T-cells. IgM secreted by B-cells aids B-cells to capture and 
internalize soluble antigen via immunoglobulin receptors, which in turn promotes their 
capacity to mount increased IgM responses .Moreover, in the presence of co-stimulatory 
molecules, B-cells are also able to present processed antigen complexed with MHC II 
molecules to T-cells(35). B-cells, which are usually stimulated by Th2 cells and 
cytokines (i.e. interleukin (IL)-4, IL-5 and IL-6), differentiate into IgG-secreting plasma 
cells. IgG plays an important role in opsonophagocytosis of and complement-induced 
cytotoxicity against pneumococci by professional phagocytes. Appropriately triggered B-
cells also release IgA, which is deposited on mucosal surfaces to protect against 
pneumococcal colonization. 
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In summary, current concepts consider polysaccharides as T-cell-independent antigens. 
However, in a recent in vitro study Stephen et al. demonstrated that capsular 
polysaccharides of serotype 1, even without conjugated protein, can be presented by 
dendritic cells to CD4+ cells (36). However, the meaning of these observations for man is 
not yet understood.  
Pneumococcal vaccines 
Introduction: The burden of pneumococcal disease in the world underlines the need for 
an effective vaccine for the same.An ideal vaccine should elicit protective immunity and 
generate memory cells, which respond to subsequent antigen exposure (37). Although 
pneumococcal diseases are frequent and vaccine development was started early, the 
development of an efficacious vaccine was not successful for a long time. The main 
reason was the low immunogenicity of polysaccharides, which are the target of 
opsonising antibodies (33). 
Pneumococcal vaccines were used as early as 1911(38).The first pneumococcal 
polysaccharide vaccines to be licensed in the United States, 2 different 6-valent 
formulations, were available shortly after World War II, but interest was very low in 
these vaccines and both were withdrawn from the market(39). A 14-valent formulation 
was licensed in 1977, and in 1983, this vaccine was replaced by the 2 currently available 
23-valent pneumococcal polysaccharide. Presently, two types of vaccines are currently in 
clinical use: polysaccharide vaccines and pneumococcal conjugate vaccines (33). 
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Polysaccharide vaccines: Polysaccharide vaccines have been available since the mid 
1980s. These vaccines contain purified capsular polysaccharides from 23 pneumococcal 
serotypes (1, 2, 3, 4, 5, 6b, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 
20, 22F, 23F and 33F). Polysaccharides primarily induce a B-cell-dependent immune 
response via release of immunoglobulin M (IgM)(40). Pneumococcal capsular 
polysaccharide antigens induce type-specific antibodies that enhance opsonization, 
phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells. After 
vaccination, an antigen-specific antibody response, indicated by a twofold or greater rise 
in serotype-specific antibody, develops within 2-3 weeks in greater than or equal to 80% 
of healthy young adults(41); however, immune responses may not be consistent among 
all 23 serotypes in the vaccine. The levels of antibodies that correlate with protection 
against pneumococcal disease have not been clearly defined.  
Antibody responses also occur in the elderly and in patients who have alcoholic cirrhosis, 
COPD, and insulin-dependent diabetes mellitus (7); however, antibody concentrations 
and responses to individual antigens may be lower among such persons than among 
healthy young adults. Persons aged greater than or equal to 2 years with anatomic or 
functional asplenia (e.g., from splenectomy or sickle cell disease) generally respond to 
pneumococcal vaccination with antibody levels comparable with those observed in 
healthy persons of the same age(42).  
Conjugate vaccines:The heptavalent pneumococcal conjugated vaccine (PCV-7) 
contains capsular polysaccharides from those pneumococci (4, 6B, 9V, 14, 18C, 19F and 
23F) that are most frequently involved in paediatric infections. Capsular polysaccharides 
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of PCV-7 are conjugated to highly immunogenic cross-reactive material 197 (CRM197), a 
non-toxic diphtheria toxoid protein. Employment of this pneumococcal vaccine is 
particularly successful in the vaccination of young children. Similar to Haemophilus 
influenzae type B conjugate vaccination, CRM197-specific type 2 helper T (Th2) cells 
interact with B-cells that have bound and internalized the polysaccharide–CRM197 
complex via polysaccharide-specific IgM and subsequently present the processed 
CRM197 protein along with MHC II to effector T-cells. This type of adaptive immune 
response is characterised by antibody isotype switching and the generation of memory B-
cells. 
PCV-7 was approved in the USA in 2000 and since then in several additional countries. 
The 23-valent polysaccharide vaccine is primarily designed for use in older children and 
adults who are at risk for pneumococcal disease. It is not licensed for use in children <2 
years of age. In some countries it is recommended by the public health authorities for all 
adults at the age of 60 years or older. 
Advantages and disadvantages of currently used Pneumococcal vaccines 
  PCV-7 elicits a mucosal immune responses in immunised hosts, most probably due to 
induction of IgA antibodies. Mucosal immunity enables asymptomatic carriers to 
eradicate colonising pneumococci of vaccine serotypes. Furthermore, PCV-7 is effective 
in preventing invasive disease progression of vaccine serotypes. A disadvantage of 
conjugate vaccines is their low coverage of pneumococcal serotypes, which, for example, 
would result in protection against just 50% of pneumococcal infections occurring in 
adults (17). In contrast to the aforementioned conjugate vaccines, polysaccharide 
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vaccines do not induce mucosal immunity and thus do not affect carrier rates(43) or herd 
immunity. In addition, the occurrence of upper and lower respiratory tract infections 
cannot be prevented by a previous pneumococcal polysaccharide-based vaccination, 
although less severe disease courses have been reported. However, a major advantage of 
such a vaccine is the large number of included pneumococcal serotypes, leading in theory 
to a vaccine coverage of approximately 80% of adult pneumococcal infections (17) 
Protection with pneumococcal vaccine 
In a trial from Spain, where 524 patients with diagnosed pneumococcal pneumonia were 
studied(44),it was shown that the portion of patients (11%) who received the 23-valent 
pneumococcal vaccine within 5 years before hospitalisation showed significantly less 
bacteraemia (15% vs. 35%) compared with non-vaccinees. Despite a less favourable 
prognosis due to higher mean age as well as a higher risk of pneumonia-induced death 
according to the Pneumonia Severity Index, vaccinees showed a quicker defervescence 
(1.7 days vs. 2.9 days) and could be released from the hospital faster (9.4 days vs. 11.3 
days). Mortality of vaccinees was also much lower (1.6% vs. 6.1%) even if this 
difference did not reach statistical significance(45). 
In a meta analysis done in 1999, it was found that vaccination with Pneumo-23 would 
reduce the risk of systemic infection due to pneumococcal types included in the vaccine 
by 83% and systemic infection due to all pneumococci by 73%.(46) 
A placebo-controlled, double-blind trial done from Eastern Gambia assessed the efficacy 
of a nine-valent pneumococcal conjugate vaccine in children. Children age 6-51 weeks 
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were randomly allocated three doses of either pneumococcal conjugate vaccine (n=8718) 
or placebo (8719), with intervals of at least 25 days between doses. Efficacy of the 
conjugate vaccine was 77% (95% confidence interval CI 51-90) against invasive 
pneumococcal disease caused by vaccine serotypes, 50% (95% confidence interval CI 21-
69) against disease caused by all serotypes, and 15% (95% confidence interval CI 7-21) 
against all-cause admissions. An efficacy of 16% (95% confidence interval CI 3-28) 
against mortality was also found.(47) 
The benefit of pneumococcal polysaccharide vaccines for public health has also been 
studied. Between 1995 and 1998, among all Stockholm residents >65 years of age 
(n = 259 627), 1, 00,242 individuals were vaccinated against pneumococcal and influenza 
infections. Subsequently, hospitalizations occurring during December 1998 to May 1999 
were recorded. Expectedly, reduced pneumonia- and influenza-associated diseases were 
observed in the immunized group. More specifically, overall mortality was lower by 57% 
(95% confidence interval 55–60%) in the vaccinee group compared with non-vaccinees 
(15.1 vs. 34.7 deaths per 1000 residents; P < 0.0001)(48). 
Groups at risk for pneumococcal disease 
Elderly: Pneumonia in elderly patients is often caused by micro aspiration of upper 
respiratory tract secretions colonized by S. pneumoniae, especially in those with an 
alteration in local defense mechanisms. Elderly individuals often have medical histories, 
underlying conditions, or chronic diseases that increase their risk of pneumonia, such as 
chronic cardiac and pulmonary conditions, diabetes mellitus, alcoholism with liver 
failure, dementia, cerebrovascular diseases, and smoking habits (49, 50). Pneumococcal 
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diseases are traditionally community-acquired pathologies. Long-term care facilities, or 
nursing homes, are unique among community settings, providing an environment rich in 
susceptible hosts and ideally suited for spread of respiratory diseases. 
The EVAN-65 study which was a long prospective study to evaluate the controversial 
effectiveness of the 23-valent PPV in older adults revealed that pneumococcal 
vaccination was associated with significant reductions in the risk of hospitalization for 
pneumonia (hazard ratio HR 0.74; 95% confidence interval CI, 0.59–0.92) and in the 
overall pneumonia rate HR, 0.79; 95% CI, 0.64–0.98). The incidence of invasive 
pneumococcal disease was low (64 cases per 100,000 person-years), and a considerable 
protective effect against invasive pneumococcal disease did not attain statistical 
significance (hazard ratio HR, 0.60; 95% confidence interval CI, 0.22–1.65). However, 
the vaccine showed a significant effectiveness of 45% to prevent pneumococcal 
pneumonia (hazard ratio HR, 0.55; 95% confidence interval  CI, 0.34–0.88). Finally, 
vaccination was associated with a significant 59% reduction in the risk of death due to 
pneumonia among vaccinated subjects (hazard ratio HR, 0.41; 95% confidence interval 
CI, 0.23–0.72)(51). 
However, in a  prospective cohort study conducted among patients above the age of 65 in 
Tarragona, Spain , it was shown that pneumococcal vaccination did not alter the risk of 
hospitalisation from pneumonia (hazard ratio HR: 0.80; 95% confidence interval (CI): 
0.50–1.28) or overall pneumonia (hazard ratio HR: 0.86; 95% confidence interval CI: 
0.56– 1.31), but the vaccine was associated with considerable reductions of death risk 
from pneumonia (hazard ratio HR: 0.28; 95% confidence interval CI: 0.09–0.83)(52). 
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A systematic review of all studies which evaluated pneumococcal vaccination in 
individuals 55 years and older showed no significant efficacy of the pneumococcal 
polysaccharide vaccine in subgroups of older adults (patients above the age of 65), 
hospitalized individuals more than 55 years of age or with risk factors like Diabetes 
Mellitus, Chronic obstructive pulmonary disease and chronic heart failure and patients in 
long term care facilities. These subgroup studies lacked power to show significant 
differences. However, observational studies have  repeatedly demonstrate efficacy in 
older adults, and the vaccine has been demonstrated to be cost-effective and safe(53). 
The efficacy of pneumococcal polysaccharide vaccine in selected populations at risk for 
serious pneumococcal infection for whom vaccination is currently recommended was 
evaluated by the Centers for Disease Control and Prevention between May 1978 and 
April 1992.  Efficacy for immunocompetent persons older than 65 years was 75% (95% 
CI, 57% to 85%)(54). 
The majority of systematic reviews did not find a significant protective effect of 
PPV(Polysaccharide pneumococcal vaccine) against noninvasive disease or overall 
pneumonia in the elderly. It is possible that PPV could not avoid the infection due to 
Pneumococcus in many elderly subjects. However, PPV may decrease the severity of 
pneumococcal infection by preventing invasion of the bloodstream and the incidence of 
the bacteraemia, it may also decrease mortality. 
Immunocompromised and people with chronic diseases: Immunocompromised people 
and people with certain chronic illness are at increased risk for invasive pneumococcal 
disease or for severe sequelae from their infections. Adults at increased risk include those 
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who are generally immunocompetent but who have chronic cardiovascular diseases (e.g., 
congestive heart failure or cardiomyopathy), chronic pulmonary diseases (e.g., chronic 
obstructive pulmonary disease {COPD} or emphysema), or chronic liver diseases (e.g., 
cirrhosis). Diabetes mellitus often is associated with cardiovascular or renal dysfunction, 
which increases the risk for severe pneumococcal illness (7). The incidence of 
pneumococcal infection is increased for persons who have liver disease as a result of 
alcohol abuse(7) .Persons with functional or anatomic asplenia (e.g., sickle cell disease or 
splenectomy) are at highest risk for pneumococcal infection, because this condition leads 
to reduced clearance of encapsulated bacteria from the bloodstream (7). Asthma has not 
been associated with an increased risk for pneumococcal disease, unless it occurs with 
chronic bronchitis, emphysema, or long-term use of systemic corticosteroids.  
As per the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program 
Network, people with chronic diseases namely chronic cardiovascular diseases, chronic 
pulmonary diseases, chronic liver diseases, diabetes, alcohol abuse, asplenia, 
immunosuppressive conditions, organ or bone marrow transplantation, chronic renal 
failure or nephrotic syndrome, and cerebrospinal fluid leakage were twice as likely as 
others to die if they develop invasive pneumococcal disease(55).  
The efficacy of pneumococcal polysaccharide vaccine in selected populations at risk for 
serious pneumococcal infection for whom vaccination is currently recommended was 
evaluated by the Centers for Disease Control and Prevention between May 1978 and 
April 1992. Overall efficacy for preventing infection caused by serotypes included in the 
vaccine was 57% (95% confidence interval CI, 45% to 66%). Efficacy among persons 
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with diabetes mellitus was 84% (95% confidence interval CI, 50% to 95%); with 
coronary vascular disease, 73% (95% confidence interval CI, 23% to 90%); with 
congestive heart failure, 69% (95% confidence interval CI, 17% to 88%); with chronic 
pulmonary diseases, 65% (95% confidence interval CI, 26% to 83%); and with anatomic 
asplenia, 77% (95% confidence interval CI, 14% to 95%)(54). However, efficacy was not 
documented for patients with alcoholism or cirrhosis, sickle cell disease, chronic renal 
failure, lymphoma, leukemia, or multiple myeloma, although sample sizes were small for 
these groups. In a study from San Francisco that reviewed cases of invasive 
pneumococcal disease that occurred during 1994–1997, the rate of invasive 
pneumococcal disease in people with AIDS was 46 times higher than was the rate among 
people without known HIV infection (53). A trial which included follow up of HIV-
infected Ugandan adults showed a survival advantage favouring vaccination (HR 0.84; CI 
0.7-1.0) (56) 
In a study from San Francisco that reviewed cases of invasive pneumococcal disease that 
occurred during 1994–1997, the rate of invasive pneumococcal disease in people with 
AIDS was 46 times higher than was the rate among people without known HIV 
infection(57). 
In a study done from Chicago which was done to evaluate the impact of pneumococcal 
vaccination on rates of pneumonia-related hospitalizations in patients with chronic 
obstructive pulmonary disease (COPD) relative to patients without , it was found that 
COPD patients with a history of pneumococcal vaccination had decreased rates of 
pneumococcal pneumonia hospitalizations after vaccination(58). 
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Smokers: Smoking is not currently an indication for pneumococcal polysaccharide 
vaccine, but smoking has recently been identified as another major risk factor for 
invasive pneumococcal disease in adults. In population-based surveillance in Texas, 
smokers who were 18–64 years old had 2.6 times the risk for invasive pneumococcal 
disease as nonsmokers who were the same age, and 31% of disease in the patients in this 
age group was attributable to smoking(59).  In a recent risk-factor study of 
immunocompetent adults aged 18–64 years, 51% of disease in this population was 
attributed to smoking, and smoking conferred a greater risk of invasive pneumococcal 
disease than that of any other characteristic studied (60). When researchers adjusted for 
other factors, people with invasive pneumococcal infection were 4.1 times more likely to 
be cigarette smokers than was the control group. The association increased with the 
number of cigarettes smoked and the number of years that the patient had smoked. Inspite 
of evidence of increased risk of pneumococcal infections in the smokers, smoking is not a 
risk factor identified under the ACIP guidelines.  
Patients in long term care facilities: Pneumococcal disease is a major problem in long-
term care facilities, and current vaccine recommendations suggest that institutionalized 
adults should receive polysaccharide vaccine. Not only are long-term care facility 
residents at high risk for sporadic pneumococcal disease as a result of their advanced age 
or the presence of chronic illnesses, but long-term care facilities also provide an optimal 
setting for pneumococcal outbreaks. Several outbreaks of infection have been reported, 
including one in which the outbreak strain was multidrug resistant (61-64). Low vaccine 
coverage may facilitate institutional outbreaks of pneumococcal disease; at the time of 
these reported outbreaks, approximately 10% of residents in the facilities had received 
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pneumococcal polysaccharide vaccine. Outbreaks of pneumococcal disease are rare 
outside of institutional settings.   
Certain ethnic groups: There are marked differences in risk for some racial and ethnic 
groups. The rate of invasive pneumococcal disease in African-American persons aged 
35–49 years exceeds that for white persons aged ≥ 65 years and African Americans at all 
ages have at least twice the risk of invasive pneumococcal disease as white persons in the 
United States(55, 59, 65-67). Rates of invasive pneumococcal infection are also higher 
among Alaska Natives(68)and certain other American Indian groups(69). The reasons for 
these differences in risk of invasive disease are not well defined. Differences in the 
prevalence of chronic diseases, such as HIV infection, AIDS, or diabetes, may contribute 
to the differences in risk between racial and ethnic groups(69, 70). However, studies that 
controlled for underlying diseases have still found higher risk of infection for African 
American persons than for persons of white race(65, 70). Although ACIP recommends 
that Alaska Natives and American Indians of all ages should receive pneumococcal 
polysaccharide vaccine because of high risk for invasive infection, current 
recommendations do not include African-American adults aged < 65 years without 
underlying illnesses. 
Current recommendations for pneumococcal vaccination(7) 
   The vaccine is both cost effective and protective against invasive pneumococcal 
infection when administered to immunocompetent persons aged greater than or equal to 2 
years or immunocompromised persons. Therefore, all persons in the following categories 
should receive the 23-valent pneumococcal polysaccharide vaccine, namely   
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1. Persons aged greater than or equal to 65 years. 
2. Persons aged 2-64 years who have chronic illnesses, such as chronic cardiovascular 
disease (e.g., congestive heart failure {CHF} or cardiomyopathies), chronic pulmonary 
disease (e.g., COPD or emphysema, but not asthma), diabetes mellitus, alcoholism, 
chronic liver disease (cirrhosis), or CSF leaks.  
3. Persons Aged 2-64 Years who have functional or anatomic asplenia 
4. Persons Aged 2-64 Years who are living in special environments or social settings, 
namely Alaskan Natives and certain American Indian populations and  residents of 
nursing homes and other long-term-care facilities.  
5. Immunocompromised persons, such as persons with HIV infection, leukemia, 
lymphoma, Hodgkins disease, multiple myeloma, generalized malignancy, chronic renal 
failure, nephrotic syndrome, or other conditions associated with immunosuppression 
(e.g., organ or bone marrow transplantation); and persons receiving immunosuppressive 
chemotherapy, including long-term systemic corticosteroids. 
Coverage with pneumococcal vaccine:The present scenario 
Scene in the developed countries: In 2004, the overall proportion of respondents aged 
>65 years reporting ever having received pneumococcal vaccine was 63.4% (CI = 62.7%-
-64.1%) in USA according to the National Health Interview Survey. Vaccination 
coverage ranged from 32.7% to 71.6%, with a median of 64.6%. In 2005, the overall 
proportion of respondents aged >65 years reporting ever having received pneumococcal 
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vaccine was 63.7% (CI = 63.1%--64.4%). Vaccination coverage ranged from 28.3% to 
71.7%, with a median of 65.7%.Pneumococcal vaccination coverage increased by 32% 
(from 42.6% to 56.3%) among persons aged >65 years from 1997 to 2005, but coverage 
has remained nearly unchanged since 2002 (56.2%)(71).  
In a descriptive study to assess the determinants of adult vaccination in inner city centres 
of USA, it was found that the rate of pneumococcal vaccination was 45% by self-report, 
55% by medical record review. The rate of vaccination was 69% for patients 65 years old 
and older, 32% for patients 50–64 years; they did not differ by race (72). The differences 
in pneumococcal vaccination rates between younger and older adults is expected, as the 
recommendation for those younger than age 65 years is to vaccinate only those with high 
risk conditions such as chronic cardiac, pulmonary, liver or kidney disease. 
In a study undertaken at two Victorian teaching hospitals to assess the coverage of 
influenza and pneumococcal vaccination among those aged above 65, it was found that 
pneumococcal vaccine coverage was 52.6 per cent (95% confidence interval CI 50.4-
54.8) as opposed to influenza vaccine coverage which was 70.9 per cent (95% confidence 
interval CI 68.9-72.9). This highlights the need for greater awareness of pneumococcal 
vaccine among practitioners and for systematic recording of vaccination status (73).  
Barriers to achieving high pneumococcal vaccination levels among adults include a) 
missed opportunities to vaccinate adults during contacts with health-care providers in 
offices, outpatient clinics, and hospitals; b) lack of vaccine delivery systems in the public 
and private sectors that can reach adults in different settings (e.g., health-care, workplace, 
and college or university settings); c) patient and provider fears concerning adverse 
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events following vaccination; and d) lack of awareness among both patients and 
providers of the seriousness of pneumococcal disease and benefits of pneumococcal 
vaccination(7). As pneumococcal vaccine effectively reduces the incidence of 
bacteraemia, the use of vaccine must be increased in accordance with recommendations. 
Scene in Asia: Published data on the extent of the pneumococcal infections is grossly 
lacking for developing countries. About 36% of aetiology proven community acquired 
pneumonia in India is assumed to be due to Pneumococcus(74). In a study from Shimla, 
out of 70 patients with community acquired pneumonia, the aetiology was obtained in 53 
(75.6%) patients. Out of these, 19 (35.8%) was due to Streptococcus pneumonia.  Studies 
on acute respiratory infections in children in most of Asia have also  highlighted the 
importance of S. pneumoniae as a common paediatric pathogen(75). 
It is estimated that 410,000 children under the age of 5 years and an equal number of 
adults die of pneumonia each year in India. An editorial from the Indian Academy of 
Paediatrics showed a striking graphic that an estimated 25% of all child deaths in India 
are due to pneumonia(76). The fact that this high a burden of pneumonia has remained 
undiminished in India in spite of economic growth and decline in child mortality due to 
other diseases is a reminder of the importance of tackling pneumonia head on with 
dedicated resources. In this setting, the role of pneumococal vaccine to reduce the 
morbidity and mortality due to pneumonia in children cannot be undermined.  
There are no studies which have evaluated the protective effect of pneumococcal 
vaccination among the susceptible adult population in India. Much work needs to be done 
 xxx
in this respect as invasive pneumococcal infections remain a leading killer among both 
children and adults on the Indian subcontinent.  
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 MATERIALS AND METHODS 
DESIGN: 
A nested case control design to determine the protective efficacy of pneumococcal 
vaccine among the susceptible adult population presenting to the Medical OPD. 
 
SUBJECTS:  
Inclusion criteria 
1) All adults above the age of 60 years at the time of recruitment 
2) Adults between 18 and 59 years with any of the following co morbidities 
i. Chronic pulmonary condition like Chronic Obstructive Pulmonary 
Disease, Interstitial Lung Disease or Bronchiectasis 
ii. Chronic cardiac condition like Coronary Artery Disease or 
Congestive Cardiac Failure 
iii. Chronic Renal Failure 
iv. Chronic Liver Disease 
v. Immunocompromised conditions like Human Immuno Virus 
Infections or chronic steroid abuse 
vi. Haematological conditions like Leukaemia, Lymphoma or 
Multiple Myeloma 
vii. Diabetes Mellitus 
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LOCATION: 
The study was conducted in the Out patient Clinics of the 3 Medical Units, Christian 
Medical College and Hospital, Vellore. 
 
DURATION: 
The study was conducted between a period of time from 01.07.2007 till 31.07.2008. 
 
METHODOLOGY: 
 
Assessment of Protective Efficacy of 23 valent Pneumococcal Polysaccharide 
Vaccine: 
Adults presenting to the Medical OPD who fulfilled the inclusion criteria were chosen for 
the study. The subjects were chosen between July 2007 and January 2008.  
The subjects thus chosen were interviewed and were educated about Pneumococcal 
vaccination and its benefits.  
The subjects’ response and willingness for vaccination was documented.  
Those who were willing to receive the vaccination were given Inj. Pneumo-23 0.5 ml 
subcutaneously after obtaining informed consent. 
All recruited subjects were followed up for a period of six months to one year. The 
follow up period lasted till the end of July 2008. 
Subjects were followed up for – 
i. Development of respiratory symptoms suggestive of pneumonia- 
fever, cough, yellow sputum 
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ii. Exacerbation of COPD 
iii. Development of symptoms of meningitis- fever, headache, 
vomiting 
iv. Episodes of hospitalization for any of the above mentioned causes 
 
Follow up of subjects: 
All recruited subjects were contacted through post/telephone every month and were 
encouraged to come to Hospital in case of any symptoms. They could also contact the 
examiner in case they developed symptoms. 
They were also given a symptom diary where they were to record all their symptoms 
even if a Hospital visit was not warranted. This was assessed at the time of routine visits. 
  
Selection of cases and controls: 
At the end of the study period, the subjects with outcomes were taken as cases and all 
those without outcomes (who did not have any complaints) were taken as controls 
(Nested Case Control Study). 
They were then analyzed as to whether they had received the vaccination. The odds of 
cases having been vaccinated was calculated and the protective efficacy of the vaccine 
was obtained. 
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Assessment of vaccination status of eligible subjects attending CMC Hospital, 
Vellore: 
A survey was conducted among the subjects visiting Medical OPD for a period of one 
week (2 OPD days of each unit) prior to recruitment of patients. The subjects were 
included according to the inclusion criteria and the number of eligible subjects visiting 
Medical OPD in one week was determined.  
The number of subjects who were prescribed and who had bought the 23 valent 
Pneumococcal vaccine from the Medical OPD in a span of 1 year prior to the study 
period was obtained from computerized treatment records kept in the Pharmacy . 
From this data, the rate of vaccination among eligible adults attending Medical OPD was 
calculated for one year before the study period as follows: 
number of people vaccinated in1 year 
52(Number of eligible subjects visiting OPD in one week) 
 
 
Assessment of causes of non vaccination from the subjects’ perspective: 
The subjects’ reasons for unwillingness for receiving the vaccine were documented and 
the reasons for non vaccination from the subjects’ perspective were described. 
 
Assessment of reasons for poor prescribing practices by Medical Consultants: 
A questionnaire was administered to all available practicing physicians in Medical OPD 
and the pattern of prescription of the vaccine and causes for non vaccination were 
obtained and described. 
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STATISTICAL ANALYSIS: 
 
Sample size estimation: 
Assuming that the adults who receive pneumococcal vaccination are 70%(O.R 0.3) less 
likely to have pneumococcal infections, the required sample size would be 80 cases and 
80 controls with 80% power, 5 % alpha level of significance and 30% prevalence of 
vaccination in the general population. 
 
Analysis: 
Statistical analysis was done using the SPSS Software version 15.0. Univariate analysis 
was done using the chi square test or fishers exact test (cell size<5) for discrete variables. 
Subsequently, the distribution of time to outcome between the vaccinated and non 
vaccinated groups was described by a log rank test. 
Odds Ratio was calculated for individual outcomes which included- 
a) Respiratory symptoms 
b) Acute exacerbation of COPD 
c) Hospitalisation 
d) Death 
Odds Ratio was also calculated for a composite outcome which included all the above 
outcomes to determine an overall efficacy rate for the vaccine. 
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 vaccinated Non vaccinated 
outcome a b 
No outcome c d 
 
 
Odds Ratio= Odds in favour of vaccination among cases (those with outcome) 
                    Odds in favour of vaccination among the controls (those without outcomes) 
 
                  =  a/b =  ad/bc 
                     c/d  
 
Vaccine efficacy was calculated as 1- Odds Ratio x 100%. 
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                                              RESULTS 
 
BASELINE CHARACTERISTICS: 
160 patients were recruited in the study period between 01.07.2007 and 31.07.2008. All 
the patients fulfilled the inclusion criteria for receiving the 23 valent pneumococcal 
vaccine. 
83 out of 160 (51.9%) [CI (44.1-59.6%)] patients received the vaccine whereas 77 out of 
160 (48.1%) [CI (40.4-55.9%)] patients did not receive the vaccine. 
 
NUMBER VACCINATED
83, 52%
77, 48% VACCINATED
NON VACCINATED
 
            Fig.1 
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Out of a total of 160 patients, 94 (59%) were males and 66 (41%) were females.  
 
SEX DISTRIBUTION
94, 59%
66, 41%
MALE
FEMALE
 
               Fig.2 
 
 
 
The minimum age of recruitment was 36 years whereas the maximum age was 88 years. 
The mean age was 61.8 years (SD 10.6) with a median age of 63 years. 
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AGE DISTRIBUTION 
Age  
Mean 61.8 
Median 63.0 
Std. deviation 10.6 
Range 52 
Maximum 88 
Minimum 36 
                                               
                                               Table.1 
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  BASELINE CHARACTERISTICS  
 
 VACCINATED NON VACCINATED 
AGE (years) 63.43±1.074 59.97±1.277 
SEX M:F 53: 30 41: 36 
RISK FACTORS (No)   
            Age > 60 Years 55 35 
            COPD 30 26 
            Cardiac disease 11 8 
            Diabetes Mellitus 61 52 
            Chronic renal 
failure 
0 4 
                 
                Table.2   
 
 
LOST TO FOLLOW UP: 
At the end of the study period, 136 (85%) [CI (79.5-90.5%)] patients had been followed 
up whereas 24 (15%) [CI (10 -20.5%)] patients were lost to follow-up (ie. could not be 
followed up even once). 18 out of 24 were in the non vaccinated group whereas 6 out of 
24 were in the vaccinated group. 
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LOST TO FOLLOW UP
136, 85%
24, 15%
FOLLOWED UP
LOST TO FOLLW UP
 
                      Fig.4 
 
RATE OF VACCINATION: 
 
No. of patients fulfilling the inclusion 
criteria for vaccination, visiting Medical 
OPD in one week 
829 
No of patients fulfilling the inclusion 
criteria for vaccination  visiting Medical 
OPD in one year 
829 x 52 = 43108 
 
No. of vaccinated patients in the previous 
one year as per records 
444 
Percentage of eligible patients who were 
vaccinated 
444/43108 x 100 = 1.03% 
 
Table.3 
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Thus 1.03%  [CI(0.93-1.13%)] of the eligible population were vaccinated from Medicine 
OPD prior to the study. 
 
VACCINATION STATUS AND DEVELOPMENT OF COMPOSITE OUTCOME: 
At the end of the study period, there were 53 patients who developed an outcome (any 
one of the following- respiratory symptoms, exacerbation of COPD, hospitalization, 
death) and 83 patients who did not develop an outcome. Out of the 53 who developed an 
outcome, 39 were in the non vaccinated group whereas 14 were in the vaccinated group. 
 
VACCINATED- OUTCOMES
63, 76%
14, 17%
6, 7%
NO COMPLAINTS
COMPLAINTS
LOST TO FOLLOW UP
 
                          Fig.5 
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NON VACCINATED-OUTCOMES
38, 50%
21, 27%
18, 23%
COMPLAINTS
NO COMPLAINTS
LOST TO FOLLOW UP
 
                       Fig.6 
  
                   VACCINATION STATUS AND COMPOSITE OUTCOME 
 
         Table.4 
Odds Ratio: (14x20)/(63x39) = 0.11. [CI (0.05-0.25)] 
Patients who had outcomes were 89% less likely to be vaccinated than the patients who 
did not have outcomes. (p value <0.001)  
 
 OUTCOMES NO 
OUTCOMES 
TOTAL ODDS 
RATIO 
P-
VALUE 
VACCINATED 14 (18.2%) 63 (81.8%) 77 0.11  
95% CI 
(0.05-0.25) 
< 0.001 
NON 
VACCINATED 
39 (66.1%) 20 (33.9%) 59   
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VACCINATION STATUS AND DEVELOPMENT OF RESPIRATORY 
SYMPTOMS: 
Among the 160 patients who were vaccinated, 38 developed symptoms of fever and 
cough with yellow sputum. Out of these 38 patients, 29 were in the non vaccinated group 
whereas 9 were in the vaccinated group. 
 
                           VACCINATION STATUS AND RESPIRATORY SYMPTOMS 
 SYMPTOMS NO 
SYMPTOMS 
TOTAL ODDS 
RATIO 
P -
VALUE
 VACCINATED 9 (11.7%) 68 (88.3%) 77 0.14 
95%CI 
(0.06-
0.32) 
<0.001 
NON 
VACCINATED 
29 (49.1%) 30 (50.9%) 59   
 
          Table.5 
Odds Ratio: (30x9)/ (29x68) = 0.14. [CI (0.06-0.32)] 
Patients who developed symptoms suggestive of pneumonia, ie fever and cough with 
yellow sputum were 86% less likely to be vaccinated as compared to the patients who did 
not develop these symptoms. (p value <0.001) 
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VACCINATION STATUS AND DEVELOPMENT OF COPD EXACERBATION: 
9 patients out of the 160 patients who were recruited developed an acute exacerbation of 
COPD. Out of these 9 patients, 2 patients belonged to the vaccinated group and 7 patients 
belonged to the non vaccinated group. 
 
                          VACCINATION STATUS AND COPD EXACERBATION 
COPD 
EXACERBATION 
NO 
EXACERBATION 
TOTAL ODDS 
RATIO 
PVALUE 
VACCINATED 2 (2.6%) 75(97.4%) 77 0.19 
95%CI 
(0.04-
0.99) 
0.04 
NON 
VACCINATED 
7(11.9%) 52(88.1%) 59   
 
Table.6 
Odds Ratio: (52x2)/ (7x75) = 0.19. [CI (0.04-0.99)] 
Patients who developed COPD exacerbations were 81% less likely to be vaccinated as  
compared to those who did not develop an exacerbation. (p value = 0.04) 
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VACCINATION STATUS AND HOSPITALISATION: 
There were 7 patients who required hospitalization for the various outcomes over a 
period of one year. Out of these 7 patients, 6 belonged to the non vaccinated group 
whereas 1 patient had been vaccinated. 
 
VACCINATION STATUS AND HOSPITALISATION 
 HOSPITALIZED NOT 
HOSPITALIZED 
TOTAL ODDS 
RATIO 
P-
VALUE 
VACCINATED 1(1.3%) 76(98.7%) 77 0.12 
95%CI 
(0.01-0.99) 
0.04 
NON 
VACCINATED 
6(10.2%) 53(89.8%) 59   
 
Table.7  
Odds Ratio: (53x1)/ (76x6) = 0.12. [CI (0.01-0.99)] 
Patients who were hospitalized were 88% less likely to be vaccinated as compared to 
those who were not hospitalized. (p value = 0.04) 
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VACCINATION STATUS AND MORTALITY: 
There were 6 deaths in a period of one year, 3 were in the vaccinated group and 3 in the 
non vaccinated group. There was no significant association between vaccination status 
and occurrence of death. (p value = 0.93) 
VACCINATION STATUS AND MORTALITY 
 
Table.8 
Odds Ratio: (56x3)/ (74x3) = 0.76. [CI (0.15-3.89) 
 
 
 
 
 
 
 
 
 
 DEATH NO DEATH TOTAL ODDS RATIO P-
VALUE 
VACCINATED 3(3.9%) 74(96.1%) 77 0.76  95% CI 
(0.15-3.89) 
0.93 
NON VACCINATED 3(5.1%) 56(94.9%) 59   
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SENSITIVITY ANALYSIS: 
Given the fact that there were more number of patients lost to follow up in the non 
vaccinated group, an analysis of the worst case scenario was also done in which all 
patients who were lost to follow up were considered to have no symptoms. 
 
VACCINATION STATUS AND DEVELOPMENT OF COMPOSITE OUTCOME: 
 
 OUTCOMES NO 
OUTCOMES
TOTAL ODDS 
RATIO 
P-
VALUE
VACCINATED 14(16.9%) 69(83.1%) 83 0.2 
95%CI(0.09-
0.40) 
<0.001 
NON 
VACCINATED 
39(50.6%) 38(49.4%) 77   
 
Table.9 
Odds Ratio: (14x38)/ (39x69) = 0.2. [CI (0.09-0.40)] 
Assuming that all patients who were lost to follow up did not develop outcomes, the odds 
ratio of patients who were vaccinated developing outcomes was 0.2. Thus, the patients 
who were vaccinated were 80% less likely to develop an outcome. (p value < 0.001)  
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VACCINATION STATUS AND DEVELOPMENT OF RESPIRATORY 
SYMPTOMS: 
 
 SYMPTOMS NO 
SYMPTOMS
TOTAL ODDS 
RATIO 
P-
VALUE
VACCINATED 9(10.8%) 74(89.2%) 83 0.2 
95%CI(0.09-
0.46) 
< 0.001 
NON 
VACCINATED 
29(37.7%) 48(62.3%) 77   
 
Table.10 
Odds Ratio: (9x48)/ (74x29) = 0.2. [CI (0.09-0.46)] 
Assuming that all patients who were lost to follow up did not develop respiratory 
symptoms, the odds ratio of patients who were vaccinated developing symptoms of 
pneumonia was 0.2, that is patients who were vaccinated were 80% less likely to develop 
symptoms of fever and cough with yellow sputum. (p value < 0.001) 
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VACCINATION STATUS AND DEVELOPMENT OF COPD EXACERBATION: 
 
 COPD 
EXACERBATION
NO COPD 
EXACERBATION
TOTAL ODDS 
RATIO 
P-
VALUE
VACCINATED 2(2.4%) 81(97.4%) 83 0.25 
95%CI(0.05-
1.23) 
0.09 
NON 
VACCINATED 
7(9.1%) 70(90.9%) 77   
 
Table.11 
Odds Ratio: (2x70)/ (81x7) = 0.25. [CI (0.05-1.23)] 
Assuming that all patients who were lost to follow up did not develop an acute 
exacerbation of COPD, there was no statistically significant association between 
vaccination status and development of an acute exacerbation of COPD. (p value = 0.09) 
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VACCINATION STATUS AND HOSPITALIZATION: 
 
Table.12 
Odds Ratio: (71x1)/ (82x6) = 0.14. [CI (0.02-1.23)] 
Assuming that all patients who were lost to follow up were not hospitalized anywhere; 
there is a statistically significant association between vaccination status and 
hospitalization. (p value = 0.04) 
 
 
 
 
 
 
 
 
 
HOSPITAL NOT IN 
HOSPITAL 
TOTAL ODDS 
RATIO 
P-
VALUE 
VACCINATED 1(1.2%) 82(98.8%) 83 0.14 
95%CI 
(0.02-1.23) 
0.04 
NON 
VACCINATED 
6(7.8%) 71(92.2%) 77   
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VACCINATION STATUS AND MORTALITY: 
 
 DEATH NO 
DEATH 
TOTAL ODDS 
RATIO 
P-
VALUE 
VACCINATED 3(3.6%) 80(96.4%) 83 0.93 
95%CI(0.18-
4.73) 
0.93 
NON VACCINATED 3(3.9%) 74(96.1%) 77   
 
Table.13 
Odds Ratio: (74x3)/ (80x3) = 0.93. [CI (0.18-4.73)] 
Assuming that all patients lost to follow up are alive, there is no significant association 
between vaccination status and occurrence of death. (p value =0.93) 
 
SUB GROUP ANALYSIS 
A subgroup analysis was done with patients who developed respiratory symptoms and 
Chest X-ray positivity which was defined as a patch on chest X-ray. 
14 patients who developed symptoms of fever and cough with yellow sputum had a patch 
on chest X-ray. Out of these patients with symptoms and a patch on chest X-ray, 13 were 
in the non vaccinated group and one was in the vaccinated group. 
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VACCINATION STATUS AND PATIENTS WITH SYMPTOMS AND XRAY 
POSITIVITY  
 XRAY 
POSITIVE 
XRAY 
NEGATIVE 
TOTAL ODDS 
RATIO 
P-
VALUE
VACCINATED 1(1.3%) 76(98.7%) 77 0.04 
95%CI(0.006-
0.364) 
<0.001 
NON 
VACCINATED 
13(22.1%) 46(77.9%) 59   
 
Table.14 
Odds Ratio: (46x1)/ (76x13) = 0.04. [CI (0.006-0.364)] 
There was a statistically significant association between the vaccination status and 
development of respiratory symptoms with chest X-ray positivity. (p value < 0.001) 
 
REASONS FOR NON VACCINATION : PATIENTS 
Out of the 77 patients who did not want to be vaccinated, 55 (72%) [CI (61.3-81.5%)] 
were not able to afford the vaccine and cited the cost of the vaccine as the reason for not 
wanting the vaccination. 6 (8%) [CI (1.8-13.8%)] patients were not convinced of the 
beneficial effects of the vaccination, 10 (13%) [CI (5.5-20.5%)] patients did not want to 
be vaccinated as they had never experienced any of the outcomes which were described. 
The reason for non vaccination was not elicited in 5 (6%) [CI (0.99-11.9%)]of the 
 liv
patients. 1 patient cited cost and not being symptomatic as the reason for not willing to be 
vaccinated. 
 
PATIENT REASONS FOR NON VACCINATION
55, 72%
6, 8%
10, 13%
1, 1%
5, 6%
COST
NOT CONVINCED
NOT SYMPTOMATIC
COST, NOT SYMPTOMATIC
NOT KNOWN
 
Fig.7 
 
REASONS FOR NON VACCINATION- DOCTORS 
The main reason cited by the physicians for not vaccinating patients was oversight. 8 of 
the 12 doctors who were interviewed said that oversight was one of the reasons for not 
prescribing pneumococcal vaccination. 6 doctors said that focusing on other medical 
problems caused them to not prescribe pneumococcal vaccination, whereas 5 doctors said 
that they did not prescribe the vaccine to all eligible patients due to the cost. None of the 
doctors cited the adverse effect related to the vaccine or a lack of evidence regarding the 
usefulness of the vaccine as a cause for non vaccination. 
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Fig.8 
 
PRESCRIPTION PATTERN 
Out of the 12 doctors who were interviewed, 9 cited old age and presence of lung 
diseases like chronic obstructive airways disease, asthma and interstitial lung disease as 
at least one of the reasons why they prescribed pneumococcal vaccine. 2 doctors said that 
patients with cardiac disease required vaccination, whereas 3 doctors said they prescribed 
pneumococcal vaccination for immuno compromised patients and 3 prescribed the 
vaccination to patients with Diabetes Mellitus. The other patient groups to whom the 
vaccine was being prescribed were patients who had had a stroke, those who had a 
previous history of community acquired pneumonia, patients who had undergone a 
splenectomy or patients who had a history of meningitis. 
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Fig.9 
 
PRESCRIBING PRACTICES 
6(50%) [CI (21.7-78.2%)] of the 12 doctors said that they occasionally prescribed the 
vaccine, whereas 4 (33%) [CI (6.7-60%)] said that they usually prescribed the vaccine. 
1(8.3%) [CI (-7.3 – 24%)] physician always prescribed the vaccine whereas 1(8.3%) [CI 
(-7.3 – 24%) never prescribed the vaccine. 
 
PRESCRIBING PRACTICES
1, 8%
4, 33%
1, 8%
6, 50%
ALWAYS
USUALLY
OCCASSIONALLY
NEVER
 
Fig.10  
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                                         DISCUSSION 
 
VACCINATION STATUS AND OUTCOMES 
The protective efficacy of 23 valent pneumococcal vaccine (PV23) in preventing severe 
invasive pneumococcal disease is well established (44, 45, 48). However PV23 is not part 
of routine adult immunization in our country and very few eligible patients receive the 
same due to poor understanding on the role of adult immunization in our country and 
doubts about efficacy against serotypes prevalent in India. The present nested case 
control study reaffirms the role of PV23 in our setting for eligible patients. Even though 
Randomized control trials are needed to confirm the efficacy of an intervention, cohorts 
and nested case control designs are easier to perform with limited resources. 
Among the 83 patients who were vaccinated, only 14 (17%) [CI (8.8-24.9%)] developed 
outcomes, while among the 77 patients who were vaccinated, 39 (50%) [CI (39.5-
61.8%)] developed symptoms. Thus the overall protective efficacy of the vaccination 
against outcomes like development of respiratory infections was 89% [CI (75-95%)] 
according to this study. This was statistically significant with a p value <0.001. This is 
similar to the study done by the Centre for Disease Control and Prevention between May 
1978 and April 1992 where they evaluated the efficacy of the vaccination among various 
risk groups and reported a 75% efficacy (95% CI, 57% to 85%) (51). This protective 
efficacy was statistically significant even in a sensitivity analysis, that is, when all the 
patients who were lost to follow up were assumed to have no outcomes during the study 
period ( p value < 0.001). Thus it can be safely said that Pneumococcal vaccination has 
an important role in the health care of adult population today. 
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This study also showed a protective efficacy of 86% [CI (68-94%)] of the vaccine against 
development of respiratory infections as described by the symptomatology of fever and 
cough with yellow sputum where 9 (10.8%) [CI (4.1-17.5%)] of the vaccinated patients 
developed respiratory symptoms as compared to 29 (37.7%) [CI (26.8-48.5%)]of the non 
vaccinated group of patients. It also showed a protective benefit of the vaccine against 
development of pneumonia (respiratory symptoms with chest x-ray evidence). Only one 
patient among the vaccinated had a patch on chest x-ray along with lower respiratory 
symptoms as compared to 13 of the non vaccinated group of patients. Assuming that all 
the patients who were lost to follow up did not develop pneumonia, this result was still 
statistically significant ( p value < 0.001).  This is comparable to the EVAN-65 study 
which studied the protective benefit of pneumococcal vaccination among adults above 65 
years and showed an overall reduction in the overall pneumonia rate HR, 0.79; 95% CI, 
0.64–0.98) (48). The study also showed a protective benefit in reducing the number of 
acute exacerbations of COPD. Out of the 9 patients who developed a COPD 
exacerbation, 2 were in the vaccinated group and 7 were in non vaccinated group. 
However, when all the patients who were lost to follow up were assumed to be free of 
COPD exacerbations, this failed to achieve statistical significance (p value= 0.089). This 
was in contrast to earlier studies which failed to show a benefit among patients with 
COPD (50). 
There was a protective benefit against hospitalizations associated with pneumonia and 
exacerbations of COPD according to this study. Of the 7 patients who were hospitalized 
for various outcomes, 6 belonged to the non vaccinated group. This was statistically 
significant with a p value of 0.04. However, the criteria for hospitalization were not 
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validated and the decision to hospitalize was not taken by a single examiner in all cases. 
This drawback has been considered as a limitation of this study. However, the reduction 
in risk for hospitalization among vaccinated individuals have been shown earlier in other 
big trials like the EVAN-65 trial (48). 
In this study, there was no protective benefit from death for people who received the 
pneumococcal vaccination. 3 people each from both the study arms died during the 
course of the study. 2 of these patients died of Type II respiratory failure during an acute 
exacerbation of COPD. Both of these patients were from the non vaccinated group. 3 
patients died of myocardial infarction and in one patient, the cause of death had not been 
determined. This is in contrast to many of the older studies which have clearly 
demonstrated a definite reduction in the risk of death (48, 49). However, this could 
probably be attributed to the fact that the follow up period was much shorter in this study 
as compared to previous studies. A longer follow up period is required to demonstrate a 
reduction in the risk of death. 
 
SURVIVAL ANALYSIS AND LOG RANK TEST 
The Survival Analysis and the Log rank test which was used to evaluate the time to 
outcome of both the vaccinated and non vaccinated groups of people showed that 
outcomes occurred at a significantly earlier time in the non vaccinated group. About 50% 
of the non vaccinated patients had already had an outcome by the 8th month of follow up. 
In the vaccinated group, 50% of the people had not yet had an outcome during the study 
period. This is due to the fact that the study period was very short. However, the 
difference in the time to outcome was statistically significant with a p value of <0.01. 
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TIME TO COMPOSITE OUTCOME 
                                                 Kaplan Meier estimates 
p value <0.01 
 group1=vaccinated 
group2=non vaccinated                                                               
Fig.11 
 
RATE OF VACCINATION 
This study showed a rate of vaccination of 1.03% [CI (0.93-1.13%)]   among the eligible 
patients who visit the Medical OPD. It is evident from this observation that only small 
proportion of eligible patients are getting vaccinated in our OPD setting even though this  
finding is limited by the fact that the seasonal variation and various other factors 
contributing to the patients’ visits to the OPD have not been taken into account. It 
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confirms the fact that pneumococcal vaccination, and indeed all adult vaccinations are 
not being given to most of the patients who are eligible for vaccination. The rate of 
vaccination in our OPD is very low in comparison with other countries like the United 
States of America where reported rates range from 28.3% to 71.7% from different parts 
of the country (67).Therefore, it can be safely concluded that there is much room for 
improvement in this respect. 
 
CAUSES OF NON VACCINATION  
The majority of the people (72%) [CI (61.3-81.5%)] who were not willing to be 
vaccinated said that cost was the main factor deterring them from receiving the 
vaccination. The 23 valent Pneumococcal vaccine ( Pneumo 23) costs Rs. 1050, which 
cannot be afforded by the majority of our population. Even though this may have a cost 
benefit in the long run, as the costs associated with a single episode of hospitalization will 
be much higher than this, more studies are needed in order to evaluate this. This also calls 
for better public health policies regarding adult vaccination. Cost effectiveness of the 
vaccine need to be widely understood even in our setting. 
The main reasons cited by the doctors for not prescribing the vaccination were oversight 
and focusing on other medical problems. Most of the practitioners are not very familiar 
with the various adult vaccinations and their protective benefits. Adult vaccination forms 
an important part of preventive health measures in the community in the present age and 
all measures must be taken to keep the doctors’ informed about these vaccines. It would 
be helpful to have immunization cards for adults as there are in children. 
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PRESCRIPTION PATTERN AND PRESCRIBING PRACTICES 
The main groups of people to whom the vaccine was being prescribed were the elderly 
and patients with underlying lung diseases. Very few doctors considered Diabetes 
Mellitus as a risk factor requiring pneumococcal vaccination. In an earlier case control 
study done by Butler et al, it was shown that  efficacy among persons with Diabetes 
Mellitus was 84%, with coronary vascular disease was 73% ,with congestive heart 
failure, 69%,with chronic pulmonary diseases, 65% and with anatomic asplenia, 77% 
(51). This shows that we need to vaccinate the people with Diabetes Mellitus and 
Coronary artery disease on a more regular basis. 
50% [CI (21.7-78.2%)] of the doctors’ said that they usually prescribed the vaccine; 
however, this is a misconception because the actual percentage of patients being 
vaccinated from the Medical OPD is only about 1 %. 
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                                     LIMITATIONS 
 
 
The study design was a nested case control study and not a randomized controlled trial. 
Subject allocation was not blinded. The subjects were recruited from OPD and later on 
assessed for development of outcomes by a single examiner, who was aware of the 
patient allocation. Therefore, the bias involved due to open assessment of outcomes 
cannot be excluded. An RCT gives the strongest empirical evidence of a treatment’s 
efficacy. Randomization of participants to the test and control arms and concealment of 
their allocation ensures that allocation bias and confounding of unknown variables are 
minimized. Nested case control studies can however provide valid and precise estimates 
of associations and is a cost-effective alternative for full-cohort analysis. 
Secondly, the rate of vaccination could have a wide error with regard to true measure of 
the number of subjects being vaccinated as the seasonal variation and other factors 
contributing to subjects’ OPD visits have not been taken into account. The number of 
eligible subjects presenting to Medical OPD was taken only for a particular length of time 
and not for the entire one year. 
Thirdly, there was a large number of subjects lost to follow up. About 15% of the study 
population has been lost to follow up. The number of subjects lost to follow up is not 
equally distributed among the cases and controls, most of the subjects who are lost to 
follow up belong to the non vaccinated group. 
The study used clinical criteria alone as outcomes. This was not substantiated by 
laboratory criteria. Hence the presence of invasive pneumococcal disease in subjects with 
outcomes has not been proved. 
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There were no validated criteria for admission to the hospital. Hospitalization was not 
always decided by the investigating examiner. However, there may have been a bias in 
deciding which patient should have been hospitalized.  
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                                         CONCLUSIONS 
 
1) The percentage of eligible adult population presenting to Medical OPD who receive 
Pneumococcal vaccination is very low, currently1.03% [CI (0.93-1.13%)].There is need 
to increase awareness among practicing physicians to prescribe the correct dose to 
eligible groups of people. 
 
2) The odds ratio for a patient with outcome (any one of the following- respiratory 
symptoms, exacerbation of COPD, hospitalization, death) being vaccinated is 0.11       
[CI (0.05-0.25)]. This means that Pneumococcal vaccination confers an 89% protective 
effect against development of total outcomes (p < 0.001). 
 
3) The odds ratio for a patient with symptoms of fever, cough and yellow sputum 
occurring during the study period being vaccinated is 0.14 [CI (0.06-0.32)] ie. 
Pneumococcal vaccination gives an 86% protective effect against symptoms of fever, 
cough and yellow sputum (p < 0.001). 
 
4) The odds ratio for a patient with acute exacerbation of COPD occurring during the 
study period being vaccinated is 0.19 [CI (0.04-0.99)] showing a protective effect 
(p=0.04). However, when the patients who have been lost to follow up are also included 
in the analysis (sensitivity analysis), the protective effect becomes non significant. This 
tells us that  exacerbations of COPD s influenced by multiple factors other than 
pneumococcal infection.  
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5) There were 7 hospitalized patients out of which one patient was vaccinated and 6 were 
not vaccinated. The odds ratio for patients who are hospitalized being vaccinated is 0.12 
[CI (0.01-0.99)] which shows a statistically significant association between vaccination 
status and hospitalization (p= 0.04). 
6) 3 vaccinated and 3 non vaccinated patients died during the study period. There was no 
protective association between Pneumococcal vaccination and death. 
 
7) The main reason for subjects declining vaccination was the cost of the vaccine. 5 out 
of 77 patients (72%) [CI (61.3-81.5%)] considered cost as the leading reason for non 
vaccination. The other reasons were that at the time of recruitment, they were not 
symptomatic (10/77 patients =13%) [CI (5.5-20.5%)] or were not convinced (6/77 
patients =8%)[CI(1.8-13.8%)]  about the need for vaccination. In 5 out of 77 patients 
(6%) [CI (0.99-11.9%)], the reason for non vaccination could not be ascertained. 
 
8) The main reasons for doctors’ not prescribing the vaccine were due to oversight and 
focusing on other medical problems. None of the doctors thought that there was a lack of 
evidence regarding the protective efficacy of the vaccine. 
 
9) The main patient groups to whom the vaccine was being prescribed were the elderly 
and patients who had underlying lung diseases. 
 
10) 6 out of 12 doctors (50%) [CI (21.7-78.2%)] were of the opinion that they 
occasionally prescribed the vaccine whereas 4 out of 12 doctors (33%) [CI (6.7-60%)] 
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said they usually prescribed the vaccine. However, this is probably a misconception as 
only about 1 % of the eligible population is being vaccinated. 
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 PATIENT PROFORMA 
 
 
Name:       
 
Sex:    
 
Marital status: M/U 
 
Hospital Number:     
 
Age:    
 
Address: 
 
Telephone number: 
 
Criteria for inclusion into the study:     Yes/ No 
 
 1. Age above 60 
  
2. Underlying pulmonary disease 
  
3. Underlying cardiac disease 
  
4. Immunocompromised states 
  
5. Diabetes Mellitus 
  
6. Chronic renal failure 
  
7. Liver disease 
 
8. Haematological conditions 
 
Vaccination status:            Yes/ No 
 
Date of vaccination: 
 
 
 
 
 
 
 
 
 lxxx
 
Reason for unwillingness:      
        (not vaccinated)                            
 
 
 
 
 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
1 Cost 
2 Not convinced 
3 Not symptomatic 
4 Not known 
5 Others 
 lxxxi
  OUTCOME DETAILS 
 
 
 
OUTCOME BLOOD 
CULTURE 
 
CSF 
GRAM 
STAIN 
AND 
CULTURE
SPUTUM 
CULTURE
CHEST 
XRAY 
HOSPITALISATION 
COPD 
EXACERBATION 
     
PNEUMONIA      
MENINGITIS      
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  PATIENT FOLLOW UP 
 
 
 
 
 
 
SUBJECT Jul 07 Aug 07 Sep 07 Oct 07 Nov 07 Dec 07 
OUTCOME       
 
 
 
 
SUBJECT Jan 08 Feb 08 Mar 08 Apr 08 May 08 Jun 08 
OUTCOME       
 
 
SUBJECT Jul 08 Aug 08 
OUTCOME   
 
 
 
 
Date of vaccination: 
 
Number of outcomes: 
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 INFORMED CONSENT FORM 
 
 
TITLE OF THE STUDY: The use of pneumococcal vaccine in a tertiary care centre in 
India 
 
 
INSTITUTION: Department of Medicine II, Christian Medical College and Hospital. 
 
HOSPITAL NO.: 
 
NATURE AND PURPOSE OF THE STUDY: You are being asked to participate in a 
study which involves receiving pneumococcal vaccine and being followed up for a period 
of 6 months to one year to assess the efficacy of the vaccine. 
 
              Benefits of being vaccinated:  Pneumococcal disease is a serious disease which 
results in much sickness and death. It can cause very serious infections in the lung 
(pneumonia), brain (meningitis) or blood (bacteremia).There is documented resistance to 
drugs like Penicillin, hence prevention through vaccination becomes important. 
 
              Adverse effects of the vaccination: It is mostly a safe vaccine. However it can 
cause minor side effects like  
• redness and pain at the site of injection.(50%) 
• fever, muscle aches or more severe local reactions.(<1%) 
• very rarely, severe allergic reactions. 
 
EXPECTED DURATION OF INVOLVEMENT: Duration of assessment will be for 
about 6 months to one year.  
 
POSSIBLE BENEFITS OF THE STUDY: The outcome of the study will help us to know 
the protective efficacy of the vaccine and the various reasons of non vaccination in our 
adult population. You will not be charged for the vaccine or the urine BINAX test. 
 
CONFIDENTIALITY: Your records and all details obtained in this study will remain 
strictly confidential at all times, but will need to be available to the doctor conducting the 
study. Your identity will not otherwise be revealed. Your personal data collected will be 
processed only for research purposes in connection with this study. You will not be 
referred to by name or identified in any report or publication. 
 
RIGHT TO WITHDRAW FROM THE STUDY: You are free to leave the study at any 
time. Your decision not to participate in this study will not affect your present or future 
medical care. 
 
CONSENT: I have read/ had read to me above information before signing this consent 
form. 
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SIGNATURE OF THE SUBJECT: 
 
 
SIGNATURE OF THE PERSON OBTAINING CONSENT: 
 
 
DATE: 
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                QUESTIONNAIRE FOR THE DOCTORS 
 
 
 
 
1.AGE        
                                                                                                                                                                              
 
2.SEX                                                                                                 
                                                                                                              
 
3.NUMBER OF YEARS OF CLINICAL EXPERIENCE  POST MD          
 
4.IN WHICH PATIENTS DO YOU GENERALLY PRESCRIBE PNEUMOCOCCAL 
VACCINE? PLEASE STATE 
 
 
 
5.ARE YOU PRESCRIBING PNEUMOCOCCAL VACCINE TO ALL PATIENTS  
WHO YOU THINK REQUIRE TO BE VACCINATED?  
                                                                                                 1- always 
                                                                                                 2- usually 
         3- occasionally 
         4- never 
 
 7.IF THE ABOVE ANSWER IS 3 OR 4 ,STATE YOUR  REASONS. 
                  
                   1- Cost 
                   2- Focusing on other medical problems                                        
                   3- Oversight 
                   4- Lack of evidence regarding efficacy 
                   5- Adverse effects of the vaccine 
                   6- Others (Please state) 
 
 
            
 
  
  
 
 
 
 
  
M F
  
1 
2 
3 
4 
1 
2 
3 
4 
5 
6 
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DATA FOR THESIS  
 
 
 
 
1. To determine the rate of pneumococcal vaccination among adult patients fulfilling 
the general indications for vaccination in Medicine OPD. 
                           No. of eligible patients in one week: 829 
                           No. of vaccinations in 8 months: 296 
 
2. Data for EXCEL sheet 
Male 1  
Female 2 
 
Vaccinated 1 
Non vaccinated 2 
 
 
Outcome 
1. COPD Exacerbation 
2.  
3. Meningitis 
4. Bactremia 
5. Pneumonia 
6. No complaints 
7. Death 
8. Hospitalisation 
 
 
 
Labs 
1.Blood c/s 
2.CSF 
3.Sputum c/s 
4.CXR 
5. 
6. Not applicable/ nil 
 
 
 
Reason for non vaccination 
1.cost 
2.not convinced 
3.Not symptomatic 
4.not known 
5. not applicable 
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Cause of death 
1.Pneumonia 
2.Meningitis 
3. Acute exacerbation 
4.others 
5. not known 
 
 
 
Lost to follow up:23 
 
Prescription 
1. Age 
2. Underlying lung disease 
3. Underlying cardiac disease 
4. Immunocompromised 
5. Diabetes Mellitus 
6. Chronic renalfailure 
7. Liver disease 
8. Haematological conditions 
9. Others 
 
 
 
Pattern 
1.always 
2.usually 
3. occasionally 
4.never 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NAME HOSP.NO AGE SEX RISK FACTORS
VIJAYA 837224 48 2 5
SAMPATH 025401B 43 1 5
VISALAKSHI 945129C 66 2 1,5
SUBRAMANIAM 577102B 60 1 5
ARUMUGAM 014000D 78 1 1,5
JEYARAMAN 025401B 65 1 1,2,5
VENNILA 286914C 53 2 5
BERNADETTE 840378 64 2 1
JEYAGOPI 482993C 49 1 5
VASANTHA 125005D 67 2 1,5
SUNDARESAN 540718B 72 1 1,2,3,5
VACCHALA 153177D 61 2 1,5
ACHUTHAN 796825C 65 1 1,5
THAYYAN 176669C 75 1 1,2,5
THIRUPURAMMA 469978A 68 2 1,2,5
SELVARAJ 23168 68 1 1,3,5
NAVANEETHAM 104448D 70 2 1,5
PONNACHI 130078B 79 2 1,2
ARUGADAN 156150C 62 1 1,5
SRI RAMULU 128978B 72 1 1,2,5
ARUMUGAM 14000 78 1 1
THARABAI 014674D 56 2 5
PARIMALA 385455 61 2 1,5
SULAIMAN 183183C 52 1 5
CHANDRASEKHAR 236770 70 1 1,5
RAJAMMA 395691 54 2 3,5
PONNAIYAN 223274A 61 1 1,3,5
NISAR AHMED 334967C 50 1 3,5
RAJENDRAN 734410C 54 1 5
BASHEER AHMED 993015B 57 1 2,5
CHANDRA.P 162606D 54 2 5
ISRAEL 814213A 77 1 1,2,5
SAMBANDAN 448737C 66 1 1,5
PRAKASAM 271337 64 1 1,2
RAJENDRAN 027890D 49 1 5
SYED NIZAR 608308B 65 1 1,5
CHAKARAI 674733C 48 1 2,5
KUMARAVEL 950439B 47 1 2,3,5
EKAMBARAM 473217C 74 1 1,5
LAKSHMI 137631D 50 2 5
PACHAIYAMMAL 907093C 56 2 3,5
ANANDAN 185416D 49 1 5
NIRMALA 159093C 70 2 1,3,5
UBAYADULLAH 978104C 53 1 5
NATARAJAN 778053C 47 1 5
ARJUNAN 142171D 73 1 1,2,5
LILLY MUNISAMY 038174D 67 2 1,3,5
FAKKURUDIAN 436762C 66 1 1,3,5
MUTHUMANICKAM 137964D 71 1 1,3,5
MOORTHY 026920C 55 1 5
ABDUL RASHID 164653D 79 2 1,2
PUGHAZHENDI 555084A 49 1 5
SEETHARAMAN 230643 72 1 1,2
JAYALAXMI 767856C 54 2 5
SHAKUNTALA 951834B 57 2 3,5
EKAMBARAM 281711C 67 1 1,2,5
MANI K 169009D 62 1 1,2,5
PARVATHY 658927C 55 2 5
RAJA D 354426C 49 1 3,5
ARJUNAN V 143120D 65 1 1,2
GOVINDAN 143220D 62 1 1,2
SUSHEELA 669944C 76 2 1,2
RAJAGOPAL 975657C 65 1 1,2
GNANA WILSON 647508C 62 1 1,2,5
PADMANABHAN 675256C 82 1 1
SHANTA 32`549B 70 2 1
CHANDRA.M 162600D 54 2 5
ANANDAN 143114D 40 2 2,5
MURALIDHARAN 196144D 36 1 5
DURAIRAJ 194029D 44 1 5
ARUNACHALAM 259653 71 1 1
SARADHA 545057 77 2 1,2
MERCY 676760A 82 2 1,2,5
RAMAJEYAM 160703D 60 1 2
SUBRAMANI 775293C 38 1 2
SARADHA 545068B 77 2 1,2,3
ESWARAN 266508C 51 1 2
BHAGAVAN DASS 567128B 63 1 1,2,5
AMMENI G 184018D 64 2 1,3
VIJAYA 799272C 48 2 5
KANNIAPPAN 965948C 58 1 2
JEYAKUMAR 811858A 56 1 5
BALA 923585 62 2 1,5
RANGANATHAN 445936C 61 1 1,5
DURAI 166215D 75 1 1,2
VENKATCHALPATHI 466673 74 1 1,2,3
SURESH 048164D 46 1 5
PATTAMMAL 577305A 68 2 1
POWN DEVARAJ 152145D 49 2 5
VINCENT 186166 64 1 1,2
MOSES 223517 66 1 1,5
PAWNAMMAL 061526D 50 2 5
GOWRIAMMAL 199735B 70 2 1,5
MURUGESAN 516817B 64 1 1,2
KRISHNAVENI 497459A 52 2 5
VEERABADRAN 312693B 74 1 5
PARVATHI 404601C 44 2 5
KASTHURI 563581A 57 2 5
KRISHNAMOORTHY 626051C 53 2 2
NAVANEETHAM 156002C 52 2 5
PONNUSAMY 252152 62 1 1,5
DEVARAJ 208104D 67 1 1,2
VENKATESAN 221465D 63 1 1,2
SUBRAMANI 162948C 80 1 1,5
LAKSHMI 927824B 67 2 1
SESHALAM 303288B 69 1 1,5,6
RAJAMMA 168069D 70 2 1
RAMBAI AMMAL 341386B 69 2 1,5
RAHIMUNISA 683677B 59 2 5
RADHA.P 521703C 68 2 1,5
BANU 130333D 50 2 2,5
VELAUDHAM 722875B 52 1 5
GAJENDRAN 116738C 45 1 6
KANNAMMAL 971985C 70 2 1
KANNAGOUNDER 504278C 63 1 1,6
GANESAN 331892 66 1 1,5
RAJAMANI 672261C 44 1 3,5
KUPPAMMA 976712C 45 2 5
PANNEER.V 354600C 59 1 5
YESTHER 107564 52 2 5
EDWAD JONES 41555 81 1 1,2,5
KUPPAMMA 405531C 52 2 2,5
NICKELSEN 781095C 52 1 5
VEERAMANI 893209C 40 1 5
BOMMI 651222A 51 2 5
GOVINDASAMY 608645A 53 1 2
BOOPALAN 399530 73 1 2
GRACE PUNITHA 493374C 58 2 5
NAGARAJAPILLAI 701245A 74 1 1,5
ATTODIL 604152A 65 2 1,2,5
DURAIKRISHNAN 448394B 72 1 1,5
DHANAM 506921 59 2 5
PATTAMMAL 965974C 75 2 1
KANNIAMMAL 100375D 60 2 5
MAHMATH BASHA 489916C 47 1 3,5,6
JEBAKANI 374234A 72 2 1,2
PONNUSAMY 647124C 67 1 1,2
MUNIAMMAL 211913D 65 2 1
SIVABHUSHANAM 125340 58 2 2,5
SUSHEELA 381655B 77 2 1,3
ANWAR BASHA 148845D 48 1 2,5
MANGALAXMI 416256C 69 2 1,5
PALANIVEL 190072D 65 1 1
DEVANESAN 974929C 63 1 1,2,5
NATARAJAN 930576C 76 1 1,2,5
BABU 943459B 72 1 1,2
LAKSMANAN 918487C 79 1 1,2
VISHWANATHAN 289426C 62 1 1,5
LAKSHMI 564992C 55 2 5
YESUPATHAM 597344C 71 1 1,2
MOHAN N 466870C 58 1 5
SAROJA 881319C 67 2 1
KANNAYAN 305295B 67 1 1,5
SUBRAMANIAM 598650B 64 1 1,5
VELU 208812D 70 1 1
THAVAMANI 903218C 60 2 2,5
JAYACHANDRAN 797222B 50 1 2
GEETHESWARI 753666B 55 2 2
ARPUTHA MMAL 703827A 88 2 1,5
JANARDHANAM 296975B 68 1 1,2,5
VACCINATION STATUDATE OF VACCINATIOUTCOME DATE OPNEUMONIA COPD
1 12.07 6 1 1
1 12.07 5 6.08 2 1
1 12.07 5 6.08 2 1
2 7.07 6 1 1
1 12.07 6 1 1
1 10.07 1 4.08 1 2
2 12.07 6 1 1
1 12.07 5 6.08 2 1
2 11.07 6 1 1
2 10.07 5 4.08 2 1
1 12.07 6 1 1
1 12.07 6 1 1
1 11.07 6 1 1
1 11.07 6 1 1
1 7.07 6 1 1
1 11.07 6 1 1
1 11.07 7 6.08 1 1
1 11.07 6 1 1
1 11.07 6 1 1
1 11.07 6 1 1
2 11.07 5,5 12.07,04 2 1
1 11.07 6 1 1
2 11.07 6 1 1
1 12.07 6 1 1
1 9.07 6 1 1
1 12.07 6 1 1
1 12.07 6 1 1
1 9.07 6 1 1
2 11.07 5,8 4.08 2 1
2 12.07 1 7.08 1 2
2 11.07 8 1.08 2 1
2 9.07 6 1 1
1 7.07 6 1 1
1 7.07 1 4.07 1 2
1 11.07 6 1 1
1 11.07 6 1 1
2 11.07 6 1 1
2 11.07 1 6.08 1 2
2 7.07 6 1 1
2 9.07 6 1 1
1 9.07 6 1 1
1 9.07 6 1 1
1 11.07 6 1 1
1 11.07 6 1 1
2 11.07 6 1 1
2 7.07 5,7,8 11.07 2 1
1 11.07 6 1 1
2 11.07 7 12.07 1 1
2 11.07 6 1 1
1 11.07 6 1 1
2 10.07 7,8 1.08 1 1
1 12.07 6 1 1
1 8.07 6 1 1
2 9.07 6 1 1
1 9.07 6 1 1
2 11.07 1 4.08 1 2
2 9.07 5 1.08 2 1
2 9.07 5 3.08 2 1
2 7.07 5 12.07 2 1
2 7.07 5 11.07 2 1
2 7.07 1,8 12.07 1 2
1 12.07 6 1 1
2 9.07 5 1.08 2 1
2 7.07 5 12.07 2 1
2 9.07 5 12.07 2 1
2 10.07 5 11.07 2 1
2 10.07 5 1.08 2 1
2 7.07 1,8 11.07 1 2
2 7.07 5 3.08 2 1
2 7.07 5 2.08 2 1
2 8.07 5 1.08 2 1
2 12.07 1 7.08 1 2
2 10.07 1 1.08 1 2
2 12.07 5 3.08 2 1
2 7.07 5 2.08 2 1
1 10.07 6 1 1
2 7.07 5 2.08 2 1
2 8.07 5 12.07 2 1
2 1.08 5 5.08 2 1
2 10.07 5 3.08 2 1
1 8.07 5,8 4.08 2 1
1 11.07 6 1 1
1 1.08 7 5.08 1 1
1 10.07 6 1 1
2 1.08 6 1 1
2 10.07 5 11.07 2 1
1 7.07 6 1 1
2 7.07 5 1.08 2 1
2 7.07 5,8 12.07 2 1
1 9.07 5 3.08 2 1
1 7.07 5 2.08 2 1
1 9.07 6 1 1
1 9.07 6 1 1
1 1.08 6 1 1
2 9.07
2 12.07 5 5.08 2 1
1 8.07 6 1 1
2 12.07
2 10.07
2 12.07
1 11.07 6 1 1
1 12.07 6 1 1
1 12.07 6 1 1
1 12.07 6 1 1
2 8.07
2 11.07
1 1.08
2 7.07
2 9.07
2 11.07
2 10.07
1 8.07
2 9.07
2 10.07 6 1 1
2 9.07 6 1 1
1 10.07 6 1 1
2 8.07 5 5.08 2 1
2 9.07
2 10.07
2 7.07 6 1 1
2 7.07 6 1 1
2 10.07
2 8.07
1 10.07 6 1 1
2 11.07
2 7.07
1 7.07 6 1 1
2 8.07 6 1 1
1 9.07 6 1 1
1 12.07
1 7.07
2 7.07 6 1 1
2 9.07 6 1 1
2 9.07 6 1 1
2 8.07 6 1 1
1 9.07 6 1 1
1 7.07
2 12.07 5 5.08 2 1
1 8.07 6 1 1
1 12.07
1 1.08 6 1 1
1 12.07 6 1 1
2 12.07
1 7.07 6 1 1
1 7.07 6 1 1
1 7.07 5 3.08 2 1
1 10.07 6 1 1
1 8.07 6 1 1
1 11.07 6 1 1
1 8.07 6 1 1
1 12.07 6 1 1
1 12.07 7 6.08 1 1
1 12.07 6 1 1
1 12.07 6 1 1
1 12.07 6 1 1
1 12.07 5 5.08 2 1
1 11.07 6 1 1
1 9.07 6 1 1
1 7.07 6 1 1
1 8.07 5 11.07 2 1
HOSPITALISATION DEATH COMPLAINLABS OUTCOMEREASON FOR NON VACCINATION
1 1 1 6 5
1 1 2 6 1 5
1 1 2 3 2 5
1 1 1 6 3
1 1 1 6 5
1 1 2 6 1 5
1 1 1 6 1
1 1 2 3 2 5
1 1 1 6 2
1 1 2 6 1 3
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 2 2 6 1 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 2 6 1 1
1 1 1 6 5
1 1 1 6 1
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 1
2 1 2 6 1
1 1 2 6 1 1
1 1 2 4 2 1
1 1 1 6 1
1 1 1 6 5
1 1 2 6 1 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 1
1 1 2 6 1 2
1 1 1 6 3
1 1 1 6 1
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 1
2 2 2 3,4 2 1
1 1 1 6 5
1 2 2 6 1 5
1 1 1 6 3
1 1 1 6 5
2 2 2 6 1 1
1 1 1 6 5
1 1 1 6 5
1 1 1 6 2
1 1 1 6 5
1 1 2 6 1 1
1 1 2 3 2 1
1 1 2 4 2 1
1 1 2 4 2 2
1 1 2 3,4 2 1
2 1 2 6 1 1
1 1 1 6 5
1 1 2 3 2 1
1 1 2 4 2 2
1 1 2 3 2 3
1 1 2 4 2 1
1 1 2 4 2 1
2 1 2 6 1 1
1 1 2 4 2 3
1 1 2 4 2 1
1 1 2 3 2 2
1 1 2 6 1 1
1 1 2 6 1 1
1 1 2 4 2 1
1 1 2 6 1 1
1 1 1 6 5
1 1 2 6 1 1
1 1 2 3 2 1
1 1 2 6 1 1
1 1 2 4 2 1
2 1 2 1,3,4 2 5
1 1 1 6 5
1 2 2 6 1 5
1 1 1 6 5
1 1 2 6 1 1
1 1 2 6 1 1
1 1 1 6 5
1 1 2 6 1 3
2 1 2 4 2 3
1 1 2 3 2 5
1 1 2 3 2 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 2 1 1
1 1 1 6 5
1
1
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
5
1
1
1
1
5
1
1 1 1 6 1,3
1 1 1 6 1
1 1 1 6 5
1 1 2 1 1
1
1
1 1 1 6 1
1 1 1 6 1
1
1
1 1 1 6 5
3
1
1 1 1 6 5
1 1 1 6 1
1 1 1 6 5
5
5
1 1 1 6 1
1 1 1 6 3
1 1 1 6 1
1 1 1 6 1
1 1 1 6 5
5
1 1 2 1 1
1 1 1 6 5
5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 2 6 1 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 1 6 5
1 1 2 1 5
1 1 1 6 5
1 1 1 6 5
1 2 2 1 5
1 1 2 1 5
CAUSE OF DEATH ORGANISM
Ps. Aeruginosa
H. influenza
5
3 Yeast, GPC
4
3Ps. Aeruginosa
Klebsiella
Klebsiella
Klebsiella
GPC in chainsand pairs
Strep. Pneumoniae
Klebsiella
Strep. Pneumoniae
4
Klebsiella
H. influenza

4
SR.NO AGE SEX PRESCRI PATTERN REASONSEXEPERIENCE
1 42 1 2,5 2 1,3 13
2 38 1 2,5,1,4 1 1,2,3 13
3 29 1 3 1,2 5
4 49 1 1,2,3,4,9 2 3 19
5 56 1 1 3 3 27
6 31 2 1,2,4 3 1,3 8
7 42 2 1 4 2
8 35 2 1,2 2 2,3 11
9 44 1 1,2,3,9 2 2,3 17
10 30 1 2 3 3 10
11 34 2 1,2,5,9 3 2 11
12 37 2 1,2,9 3 1 12
NAME HOSP.NO VACCINATION STATUS DATE OF ENROLMENDATE OF O
VIJAYA 837224 1 12.07
SAMPATH 025401B 1 12.07 6.08
VISALAKSHI 945129C 1 12.07 6.08
SUBRAMANIAM 577102B 2 7.07
ARUMUGAM 014000D 1 12.07
JEYARAMAN 025401B 1 10.07 4.08
VENNILA 286914C 2 12.07
BERNADETTE 840378 1 12.07 6.08
JEYAGOPI 482993C 2 11.07
VASANTHA 125005D 2 10.07 4.08
SUNDARESAN 540718B 1 12.07
VACCHALA 153177D 1 12.07
ACHUTHAN 796825C 1 11.07
THAYYAN 176669C 1 11.07
THIRUPURAMMA 469978A 1 7.07
SELVARAJ 23168 1 11.07
NAVANEETHAM 104448D 1 11.07 6.08
PONNACHI 130078B 1 11.07
ARUGADAN 156150C 1 11.07
SRI RAMULU 128978B 1 11.07
ARUMUGAM 14000 2 11.07 12.07,04.08
THARABAI 014674D 1 11.07
PARIMALA 385455 2 11.07
SULAIMAN 183183C 1 12.07
CHANDRASEKHAR 236770 1 9.07
RAJAMMA 395691 1 12.07
PONNAIYAN 223274A 1 12.07
NISAR AHMED 334967C 1 9.07
RAJENDRAN 734410C 2 11.07 4.08
BASHEER AHMED 993015B 2 12.07 7.08
CHANDRASEKHAR 162606D 2 11.07 1.08
ISRAEL 814213A 2 9.07
SAMBANDAN 448737C 1 7.07
PRAKASAM 271337 1 7.07 4.07
RAJENDRAN 027890D 1 11.07
SYED NIZAR 608308B 1 11.07
CHAKARAI 674733C 2 11.07
KUMARAVEL 950439B 2 11.07 6.08
EKAMBARAM 473217C 2 7.07
LAKSHMI 137631D 2 9.07
PACHAIYAMMAL 907093C 1 9.07
ANANDAN 185416D 1 9.07
NIRMALA 159093C 1 11.07
UBAYADULLAH 978104C 1 11.07
NATARAJAN 778053C 2 11.07
ARJUNAN 142171D 2 7.07 11.07
LILLY MUNISAMY 038174D 1 11.07
FAKKURUDIAN 436762C 2 11.07 12.07
MUTHUMANICKAM 137964D 2 11.07
MOORTHY 026920C 1 11.07
ABDUL RASHID 164653D 2 10.07 1.08
PUGHAZHENDI 555084A 1 12.07
SEETHARAMAN 230643 1 8.07
JAYALAXMI 767856C 2 9.07
SHAKUNTALA 951834B 1 9.07
EKAMBARAM 281711C 2 11.07 4.08
MANI K 169009D 2 9.07 1.08
PARVATHY 658927C 2 9.07 3.08
RAJA D 354426C 2 7.07 12.07
ARJUNAN V 143120D 2 7.07 11.07
GOVINDAN 143220D 2 7.07 12.07
SUSHEELA 669944C 1 12.07
RAJAGOPAL 975657C 2 9.07 1.08
GNANA WILSON 647508C 2 7.07 12.07
PADMANABHAN 675256C 2 9.07 12.07
SHANTA 32`549B 2 10.07 11.07
CHANDRASEKHAR 162600D 2 10.07 1.08
ANANDAN 143114D 2 7.07 11.07
MURALIDHARAN 196144D 2 7.07 3.08
DURAIRAJ 194029D 2 7.07 2.08
ARUNACHALAM 259653 2 8.07 1.08
SARADHA 545057 2 12.07 7.08
MERCY 676760A 2 10.07 1.08
RAMAJEYAM 160703D 2 12.07 3.08
SUBRAMANIAM 775293C 2 7.07 2.08
SARADHA 545068B 1 10.07
ESWARAN 266508C 2 7.07 2.08
BHAGAVAN DASS 567128B 2 8.07 12.07
AMMENI G 184018D 2 1.08 5.08
VIJAYA 799272C 2 10.07 3.08
KANNIAPPAN 965948C 1 8.07 4.08
JEYAKUMAR 811858A 1 11.07
BALA 923585 1 1.08 5.08
RANGANATHAN 445936C 1 10.07
DURAI 166215D 2 1.08
VENKATCHALPATHI 466673 2 10.07 11.07
SURESH 048164D 1 7.07
PATTAMMAL 577305A 2 7.07 1.08
POWN DEVARAJ 152145D 2 7.07 12.07
VINCENT 186166 1 9.07 3.08
MOSES 223517 1 7.07 2.08
PAWNAMMAL 061526D 1 9.07
GOWRIAMMAL 199735B 1 9.07
MURUGESAN 516817B 1 1.08
KRISHNAVENI 497459A 2 9.07
VEERABADRAN 312693B 2 12.07 5.08
PARVATHI 404601C 1 8.07
KASTHURI 563581A 2 12.07
KRISHNAMOORTHY 626051C 2 10.07
NAVANEETHAM 156002C 2 12.07
PONNUSAMY 252152 1 11.07
DEVARAJ 208104D 1 12.07
VENKATESAN 221465D 1 12.07
SUBRAMANIAM 162948C 1 12.07
LAKSHMI 927824B 2 8.07
SESHALAM 303288B 2 11.07
RAJAMMA 168069D 1 1.08
RAMBAI AMMAL 341386B 2 7.07
RAHIMUNISA 683677B 2 9.07
RADHA.P 521703C 2 11.07
BANU 130333D 2 10.07
VELAUDHAM 722875B 1 8.07
GAJENDRAN 116738C 2 9.07
KANNAMMAL 971985C 2 10.07
KANNAGOUNDER 504278C 2 9.07
GANESAN 331892 1 10.07
RAJAMANI 672261C 2 8.07 5.08
KUPPAMMA 976712C 2 9.07
PANNEER.V 354600C 2 10.07
YESTHER 107564 2 7.07
EDWAD JONES 41555 2 7.07
KUPPAMMA 405531C 2 10.07
NICKELSEN 781095C 2 8.07
VEERAMANI 893209C 1 10.07
BOMMI 651222A 2 11.07
GOVINDASAMY 608645A 2 7.07
BOOPALAN 399530 1 7.07
GRACE PUNITHA 493374C 2 8.07
NAGARAJAPILLAI 701245A 1 9.07
ATTODIL 604152A 1 12.07
DURAIKRISHNAN 448394B 1 7.07
DHANAM 506921 2 7.07
PATTAMMAL 965974C 2 9.07
KANNIAMMAL 100375D 2 9.07
MAHMATH BASHA 489916C 2 8.07
JEBAKANI 374234A 1 9.07
PONNUSAMY 647124C 1 7.07
MUNIAMMAL 211913D 2 12.07 5.08
SIVABHUSHANAM 125340 1 8.07
SUSHEELA 381655B 1 12.07
ANWAR BASHA 148845D 1 1.08
MANGALAXMI 416256C 1 12.07
PALANIVEL 190072D 2 12.07
DEVANESAN 974929C 1 7.07
NATARAJAN 930576C 1 7.07
BABU 943459B 1 7.07 3.08
LAKSMANAN 918487C 1 10.07
VISHWANATHAN 289426C 1 8.07
LAKSHMI 564992C 1 11.07
YESUPATHAM 597344C 1 8.07
MOHAN N 466870C 1 12.07
SAROJA 881319C 1 12.07 6.08
KANNAYAN 305295B 1 12.07
SUBRAMANIAM 598650B 1 12.07
VELU 208812D 1 12.07
THAVAMANI 903218C 1 12.07 5.08
JAYACHANDRAN 797222B 1 11.07
GEETHESWARI 753666B 1 9.07
ARPUTHAM 703827A 1 7.07
JANARDHANAM 296975B 1 8.07 11.07
OUTCOME OUTCOMETIME TO OUTCOME PRESENT Jul-07 Aug-07 Sep-07 Oct-07
6 1
5 6 2
5 6 2
6 1 6 6 6 6
6 1
1 7 2 6
6 1
5 6 2
6 1
5 6 2 6
6 1
6 1
6 1
6 1
6 1 6 6 6 6
6 1
7 7 2
6 1
6 1
6 1
8 5,5 1 2
6 1
6 1
6 1
6 1 6 6
6 1
6 1
6 1 6 6
5 5 2
1 7 2
8 2 2
6 1 6 6
6 1 6 6 6 6
1 9 2 6 6 6 6
6 1
6 1
6 1
1 7 2
6 1 6 6 6 6
6 1 6 6
6 1 6 6
6 1 6 6
6 1
6 1
6 1
5,7,8 4 2 6 6 6 6
6 1
7 1 2
6 1
6 1
7,8 3 2 6
6 1
6 1 6 6
6 1 6 6
6 1 6 6
1 5 2
5 4 2 6 6
5 6 2 6 6
5 5 2 6 6 6 6
5 4 2 6 6 6 6
1,8 5 2 6 6 6 6
6 1
5 4 2 6 6
5 5 2 6 6 6 6
5 5 2 6 6
5 4 2 6
5 3 2 6
1,8 4 2 6 6 6 6
5 8 2 6 6 6 6
5 7 2 6 6 6 6
5 5 2 6 6 6
1 7 2
1 3 2 6
5 4 2
5 7 2 6 6 6 6
6 1 6
5 7 2 6 6 6 6
5 4 2 6 6 6
5 4 2
5 5 2 6
5,8 8 2 6 6 6
6 1
7 4 2
6 1 6
6 1
5 1 2 6
6 1 6 6 6 6
5 6 2 6 6 6 6
5,8 5 2 6 6 6 6
5 6 2 6 6
5 7 2 6 6 6 6
6 1 6 6
6 1 6 6
6 1
5 5 2
6 1 6 6 6
6 1
6 1
6 1
6 1
6 1 6
6 1 6 6
6 1 6
5 9 2 6 6 6
6 1 6 6 6 6
6 1 6 6 6 6
6 1 6
6 1 6 6 6 6
6 1 6 6 6
6 1 6 6
6 1 6 6 6 6
6 1 6 6
6 1 6 6
6 1 6 6 6
6 1 6 6
5 5 2
6 1 6 6 6
6 1
6 1
6 1 6 6 6 6
6 1 6 6 6 6
5 8 2 6 6 6 6
6 1 6
6 1 6 6 6
6 1
6 1 6 6 6
6 1
7 6 2
6 1
6 1
6 1
5 5 2
6 1
6 1 6 6
6 1 6 6 6 6
5 3 2 6 6 6
Nov-07 Dec-07 Jan-08 Feb-08 Mar-08 Apr-08 May-08 Jun-08 Jul-08
6 6 6 6 6 6 6
6 6 6 6 6 6 5 6
6 6 6 6 6 6 5 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 1 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 5 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 1 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 7
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 5 6 6 6 5 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 5 6 6 6
6 6 6 6 6 6 6 1
6 6 8 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 1 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 1 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
5,7,8
6 6 6 6 6 6 6 6 6
6 7
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 7,8
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 1 6 6 6
6 6 5 6 6 6 6 6 6
6 6 6 6 5 6 6 6
6 5 6 6 6 6 6 6 6
5 6 6 6 6 6 6 6 6
6 1,8 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 5 6 6 6 6 6 6
6 5 6 6 6 6 6 6 6
6 5 6 6 6 6 6 6 6
5 6 6 6 6 6 6 6 6
6 6 5 6 6 6 6 6 6
1,8 6 6 6 6 6 6 6 6
6 6 6 6 5 6 6 6 6
6 6 6 5 6 6 6 6 6
6 6 5 6 6 6 6 6 6
6 6 6 6 6 6 6 1
6 6 1 6 6 6 6 6 6
6 6 6 5 6 6 6 6
6 6 6 5 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 5 6 6 6 6 6
6 5 6 6 6 6 6 6 6
6 6 6 5 6 6
6 6 6 6 5 6 6 6 6
6 6 6 6 6 5,8 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 5 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6
5 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 5 6 6 6 6 6 6
6 5,8 6 6 6 6 6 6 6
6 6 6 6 5 6 6 6 6
6 6 6 5 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6
6 6 6 6 6 5 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 5 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 5 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 5 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 7
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6
6 6 6 6 6 5 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
6 6 6 6 6 6 6 6 6
5 6 6 6 6 6 6 6 6
Aug-08
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
